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Abstract
Background: Severe bacterial infections remain a major challenge in intensive care units because of their high
prevalence and mortality. Adequate antibiotic exposure has been associated with clinical success in critically ill
patients. The objective of this study was to investigate the target attainment of standard meropenem dosing in a
heterogeneous critically ill population, to quantify the impact of the full renal function spectrum on meropenem
exposure and target attainment, and ultimately to translate the findings into a tool for practical application.
Methods: A prospective observational single-centre study was performed with critically ill patients with severe
infections receiving standard dosing of meropenem. Serial blood samples were drawn over 4 study days to determine
meropenem serum concentrations. Renal function was assessed by creatinine clearance according to the Cockcroft
and Gault equation (CLCRCG). Variability in meropenem serum concentrations was quantified at the middle and end of
each monitored dosing interval. The attainment of two pharmacokinetic/pharmacodynamic targets (100%T>MIC,
50%T>4×MIC) was evaluated for minimum inhibitory concentration (MIC) values of 2 mg/L and 8 mg/L and standard
meropenem dosing (1000 mg, 30-minute infusion, every 8 h). Furthermore, we assessed the impact of CLCRCG on
meropenem concentrations and target attainment and developed a tool for risk assessment of target non-attainment.
Results: Large inter- and intra-patient variability in meropenem concentrations was observed in the critically ill
population (n = 48). Attainment of the target 100%T>MIC was merely 48.4% and 20.6%, given MIC values of 2 mg/L and
8 mg/L, respectively, and similar for the target 50%T>4×MIC. A hyperbolic relationship between CLCRCG (25–255 ml/
minute) and meropenem serum concentrations at the end of the dosing interval (C8h) was derived. For infections with
pathogens of MIC 2 mg/L, mild renal impairment up to augmented renal function was identified as a risk factor for
target non-attainment (for MIC 8 mg/L, additionally, moderate renal impairment).
Conclusions: The investigated standard meropenem dosing regimen appeared to result in insufficient meropenem
exposure in a considerable fraction of critically ill patients. An easy- and free-to-use tool (the MeroRisk Calculator) for
assessing the risk of target non-attainment for a given renal function and MIC value was developed.
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Background
Severe infections remain a major issue in the intensive
care unit (ICU) because of their high prevalence and
high mortality rates among critically ill patients [1].
Hence, rational antibiotic therapy is especially important
in this vulnerable population. Apart from an appropriate
activity spectrum and early initiation of antibiotic ther-
apy, a dosing regimen leading to adequate therapeutic
antibiotic concentrations and exposure is crucial [2–5].
Adequate antibiotic exposure not only has been found
to improve clinical success but also has been suggested
to reduce resistance development [6, 7]. At the same
time, pathophysiological changes in critically ill patients,
including organ dysfunction or altered fluid balance,
might substantially influence antibiotic concentrations
and increase the risk of inadequate antibiotic exposure.
As a second challenge, infections in these patients are
often caused by pathogens with lower susceptibility (i.e.,
higher minimum inhibitory concentration [MIC]) than
in other clinical settings [8–11].
Meropenem is a broad-spectrum carbapenem β-
lactam antibiotic frequently used to treat severe bacterial
infections in critically ill patients, such as those with se-
vere pneumonia, complicated intra-abdominal infec-
tions, complicated skin and soft tissue infections, or
sepsis [12]. For these indications, the approved standard
dosing regimens for adults (intact renal function [RF])
include 500 mg or 1000 mg administered as short-term
infusions every 8 h; for other indications, doses up to
2000 mg are recommended [12]. Meropenem is a hydro-
philic molecule with very low plasma protein binding of
approximately 2% [13]. It is excreted primarily via the
kidney, predominantly by glomerular filtration but also
by active tubular secretion [14]. Meropenem has been
shown to be readily dialysable and effectively removed
by haemodialysis [15–17]. As a β-lactam antibiotic, mer-
openem shows time-dependent activity; that is, its anti-
bacterial activity is linked to the percentage of time that
meropenem concentrations exceed the MIC value of a
pathogen (%T>MIC) [18]. The attainment of the pharma-
cokinetic/pharmacodynamic (PK/PD) index %T>MIC has
been associated with clinical success in patients treated
with meropenem [19–21]. For example, Ariano et al.
demonstrated that the probability of clinical response
was 80% when %T>MIC was 76–100 in febrile neutro-
penic patients with bacteraemia but only 36% when
%T>MIC was between 0 and 50 [20].
Previous studies have revealed large inter-patient vari-
ability in meropenem concentrations after standard dos-
ing in critically ill patients [22–24], which resulted in
inadequate meropenem exposure in a relevant fraction
of patients [23, 25]. However, in most of these studies,
only limited numbers of patients and/or rather homoge-
neous patient sub-groups have been investigated. Hence,
the identified variability in meropenem exposure might
not have adequately reflected a typically heterogeneous
critically ill population. In previous analyses, RF has
been shown to be a major cause of variability in merope-
nem exposure [23, 24, 26–31] and, as a consequence, to
be influential on the attainment of specific target con-
centrations [25, 32, 33]. However, the impact of kidney
function on target attainment has been assessed primar-
ily for distinct RF classes but not yet in a coherent quan-
titative framework for a population covering the full
spectrum of RF ranging from dialysis/severe renal im-
pairment (RI) to augmented renal clearance.
The aims of this study were (1) to quantify inter- and
intra-individual variability of meropenem serum concen-
trations in a heterogeneous critically ill population cov-
ering the full spectrum of RF classes after meropenem
standard dosing, (2) to investigate the attainment of two
different PK/PD targets, (3) to assess the impact of RF
on meropenem exposure and consequently target attain-
ment and (4) ultimately to develop an easy-to-use risk
assessment tool allowing identification and quantifica-
tion of the risk of target non-attainment for a particular
patient on the basis of the patient’s RF.
Methods
Clinical study
This prospective observational study was conducted at
three ICUs within the Department of Anaesthesiology,
University Hospital, LMU Munich, Germany. The study
protocol (ClinicalTrials.gov identifier NCT01793012)
was approved by the Institutional Review Board of the
Medical Faculty of the LMU Munich, Germany. Criteria
for inclusion comprised the presence of severe infection
(confirmed or suspected by clinical assessment), age ≥
18 years and therapy with meropenem (including pos-
sible de-escalation; clinical assessment independent from
the study). Patients were excluded in case of a planned
hospitalisation < 4 days or meropenem administration >
48 h prior to study start. Written informed consent to
participate was obtained from all patients or their legal
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representatives. All patients received standard doses of
meropenem as 30-minute infusions three times per day
(see Additional file 1: Study design, Figure S1a). Multiple
arterial blood samples were collected for the quantifica-
tion of meropenem concentrations over a study period
of 4 days. Intensive sample collection was performed
during all three dosing intervals of study day 1 and dur-
ing the first dosing interval of study days 2–4. An add-
itional single minimum meropenem concentration
(Cmin) sample before the next dose was collected for the
third dosing interval of days 2 and 3. The planned sam-
pling time points per intensively monitored dosing inter-
val were as follows: 15 minutes, 30 minutes, 1.5 h, 4 h,
and 8 h (directly before next dose; Cmin) after the start
of infusion (see Additional file 1: Study design, Figure
S1b). The exact sampling time points were recorded by
the medical staff. In addition, patient-specific data such
as diagnosis, demographics, disease scores and labora-
tory data (e.g., serum creatinine) were recorded during
the study period. Creatinine clearance was estimated ac-
cording to the Cockcroft and Gault equation (CLCRCG
[34]) on the basis of daily measured serum creatinine
(Jaffe assay):
CLCRCG
ml
min
 
¼ ð140age ½yearsÞ⋅ body weight½kg
72⋅ serum creatinine mgdl
  ⋅ ð0:85 if femaleÞ
In addition, pathogens identified in specimens col-
lected from the patients (between 3 days before and
3 days after the study period) were recorded.
Bioanalytical method for meropenem concentration
Blood samples were immediately sent to the Institute of
Laboratory Medicine, University Hospital, LMU Munich
and centrifuged. Serum samples were stored at −80 °C
until total meropenem serum concentration was quanti-
fied by using a validated liquid chromatography-tandem
mass spectrometry method described previously [35].
Briefly, sixfold deuterated meropenem was used as an
internal standard, and validation revealed good analytical
performance, with an inaccuracy of less than or equal to
± 4% relative error and imprecision ≤ 6% coefficient of
variation (CV).
Variability of meropenem concentrations
To quantify inter- and intra-individual variability of mer-
openem serum concentrations, measured Cmin values
were first analysed without regard to the actual hetero-
geneous sampling time points or administered doses.
Inter-individual variability was evaluated by a summary
statistical analysis of all available Cmin values; for de-
scription of intra-individual variability, the ratios of the
maximum and minimum Cmin values
Cmin max
Cmin min
 
of all
dosing intervals monitored within a patient were
statistically summarised. Summary statistics included
median, range, 95% CI and %CV.
In order to exclude a potential impact of dose- and sam-
pling time point-related variability on the meropenem
minimum concentrations, dose-normalised meropenem
concentrations (to a dose of 1000 mg, assuming linear PK)
at two specific time points (4 h [C4h] and 8 h [C8h] after
infusion start) were calculated, and the variability was
evaluated as described above. C4h and C8h values were de-
termined by linear regression (if more than two data
points) or linear interpolation (if two data points) of the
logarithmised data in the declining phase of each
concentration-time profile. In case of a coefficient of de-
termination (R2) < 0.9, being associated with two distinct
phases in the declining part of the concentration-time
profile, a separate linear interpolation/regression was per-
formed for each of these phases.
Pharmacokinetic/pharmacodynamic target attainment
To evaluate the achievement of therapeutically ad-
equate meropenem serum concentrations, PK/PD
target attainment was assessed for a broad MIC
range from 0.25 mg/L to 8 mg/L, with a special
focus on MIC 2 mg/L and MIC 8 mg/. The two
values are common European Committee on Anti-
microbial Susceptibility Testing (EUCAST) suscep-
tible/intermediate (S/I) and intermediate/resistant (I/
R) MIC breakpoints for relevant bacteria, such as
Enterobacteriaceae, Pseudomonas spp. or Acinetobac-
ter spp. [36]. The target 100%T>MIC (i.e., meropenem
serum concentrations exceeding one times the MIC
for the entire dosing interval) was selected because
it has previously been shown to improve clinical
cure and bacteriological eradication in patients with
serious bacterial infections treated with β-lactam an-
tibiotics [20, 37]. In accordance with other studies,
50%T>4×MIC (i.e., meropenem serum concentration
exceeding four times the MIC for half of the dosing
interval) was chosen as a second target [38–40].
Owing to the negligible protein binding of merope-
nem (2%), total meropenem serum concentrations
were used for all analyses [13, 41].
To evaluate the attainment of the targets 100%T>MIC
and 50%T>4×MIC, the predicted C4h and C8h values of each
dosing interval were evaluated regarding the achievement
of the above-mentioned thresholds (one or four times the
MIC breakpoints) for all patients not undergoing continu-
ous renal replacement therapy (CRRT). Additionally, tar-
get attainment was evaluated for a dose of 2000 mg
meropenem based on the extrapolated C4h and C8h values
(assuming linear PK). Dosing was considered adequate if
the target was attained in ≥ 90% of the monitored dosing
intervals [41].
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Impact of renal function on meropenem exposure and
target attainment
To investigate the impact of RF on meropenem expos-
ure, CLCRCG was related to C4h and C8h values (at pa-
tient level using the median individual CLCRCG of a
patient, and at sample level using single CLCRCG values).
For non-CRRT patients, the relationship between
CLCRCG and C8h values was quantified by weighted lin-
ear least squares regression in double logarithmic scale 
C8h ¼ α⋅ 1ðCLCRCGÞβ
!
. For further details, see Additional
file 2: Regression model for risk calculation.
Target attainment at sample level was stratified by the
following classes of RF or RI on the basis of CLCRCG
[42–44]: severe RI 15–29 ml/minute, moderate RI 30–
59 ml/minute, mild RI 60–89 ml/minute, normal RF
90–129 ml/minute and augmented RF ≥ 130 ml/minute.
All analyses described here and previously were per-
formed using the software R, version 3.3.2 (R Founda-
tion for Statistical Computing, Vienna, Austria).
Risk assessment tool
A tool for the risk assessment of target non-attainment
based on the RF was developed using Excel 2016 soft-
ware with Visual Basic for Applications (Microsoft Cor-
poration, Redmond, WA, USA). In the Excel tool, the
quantified CLCRCG-C8h relationship for non-CRRT pa-
tients, the prediction interval around this relationship
and the computation of the risk of target (100%T>MIC)
non-attainment for given CLCRCG and MIC values were
implemented. For further details, see Additional file 2:
Regression model for risk calculation.
Results
Clinical study
Patient characteristics
A total of 48 patients (27 male, 21 female) were included
in the study (see Table 1). Of these patients, 83% suffered
from sepsis, which was most frequently caused by pneu-
monia or peritonitis (75% or 20% of the sepsis patients,
respectively). Pathogens detected in the patients com-
prised Enterobacteriaceae, non-fermenters (e.g., Pseudo-
monas spp.), Staphylococcus spp., Streptococcus spp.,
Enterococcus spp., Bacillus spp., Clostridium spp., Bac-
teroides spp., Mycoplasma spp., Candida spp. and Asper-
gillus spp. The patient group covered broad ranges of
age (24–84 years), body mass index (16–49 kg/m2) and
severity of illness (Acute Physiology and Chronic Health
Evaluation II [APACHE II] score 11–42). RF determined by
CLCRCG was highly variable, ranging from severely impaired
to augmented RF (first study day 24.8–191 ml/minute).
Seven patients received CRRT, and six patients underwent
extracorporeal membrane oxygenation (ECMO). Twenty-
eight patients were post-lung or post-liver transplant
recipients.
Meropenem dosing and sampling
During the study period, patients were treated with
1000 mg (npatients = 47) or 2000 mg (npatients = 1) of mer-
openem administered as 30-minute infusions approxi-
mately every 8 h (median 8 h, 95% CI 6.94–9.19 h). A
total of 1376 blood samples (median per patient 31)
were taken during 349 dosing intervals (median per pa-
tient 8, range per patient 4–8). Of the measurements,
23.5% (n = 324) were Cmin samples, which were collected
7.92 h (median) after infusion start (95% CI 6.85–
9.08 h). Very few serum concentrations (0.36% of data)
revealed an implausible increase in the terminal part of
the concentration-time profiles and were therefore ex-
cluded from the data analyses (red data points in Fig. 1).
Variability of meropenem concentrations
Large inter-individual variability was observed for both
the observed Cmin values (see Fig. 2) and the calculated
concentrations C8h and C4h (see Table 2). Whereas inter-
individual variability in Cmin and C8h was particularly
large, varying in both concentrations by up to a factor of
approximately 1000 between patients, C4h values were
slightly less variable (Cmin range 0.03–30.0 mg/L, 104
CV%; C8h range 0.0426–30.0 mg/L, 110 CV%; C4h range
0.933–43.3 mg/L, 69.9 CV%). Apart from inter-
individual variability, large intra-individual variability
was identified (see Table 2). Particularly Cmin (see Fig. 1)
and C8h values showed large variability, with concentra-
tions varying in median by twofold to more than tenfold
within a patient (range of ratios Cmin maxCmin min : 1.3–10.9, range
of ratios C8h maxC8h min : 1.22–11.4). Intra-individual variability in
C4h values was slightly lower, but the C4h values within a
patient still varied up to more than fivefold (range of ra-
tios C4h maxC4h min : 1.10–5.47).
Pharmacokinetic/pharmacodynamic target attainment
For infections in non-CRRT patients with pathogens of
MIC 2 mg/L, both investigated targets were attained in
approximately half of the dosing intervals monitored,
with slightly higher attainment for the 50%T>4×MIC tar-
get (56%) than for the 100%T>MIC target (48%; see
Table 3). When extrapolating the data to a dose of
2000 mg, target attainment was substantially higher, with
91% and 78% for the targets 50%T>4×MIC and
100%T>MIC, respectively (see Additional file 3: PK/PD
target attainment, Table S2).
Given an MIC of 8 mg/L, the target 100%T>MIC was
attained only in about one-fifth of the monitored
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Table 1 Patient characteristics on study day 1
Abbreviations: APACHE II Acute Physiology And Chronic Health Evaluation II [53], ARDS Acute respiratory distress syndrome, BMI Body mass index, CLCRCG
Creatinine clearance estimated according to Cockcroft and Gault equation [34], CRP C-reactive protein, CRRT Continuous renal replacement therapy, CVVH Continuous
venovenous haemofiltration, CVVHD Continuous venovenous haemodialysis, CVVHDF Continuous venovenous haemodiafiltration, ECMO Extracorporeal membrane
oxygenation, IL-6 Interleukin 6, SOFA Sepsis-related Organ Failure Assessment [54]
1In relation to total number of patients with sepsis
2In relation to total number of patients with pneumonia
3Abdominal wall abscess
4In relation to total number of patients with CRRT
5Transplant within last 28 days
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Fig. 1 Individual meropenem serum concentration-time profiles. Number above individual plot is patient identifier. Circles represent measured
meropenem concentrations. Red circles represent meropenem concentrations excluded from analyses (0.36%; see text). Lines represent connection
of consecutively sampled meropenem concentrations; that is, gaps represent non-monitored dosing intervals or missing planned meropenem
concentration measurements
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meropenem dosing intervals; attainment of the target
50%T>4×MIC was very low (7%; see Table 3). When extrapo-
lating to a dose of 2000 mg, the attainment of 100%T>MIC
was approximately twice as high as for a dose of 1000 mg
(38.1% vs. 20.6%); the attainment of 50%T>4×MIC was even
about four times as high (27.4% vs. 7.17%) (see Additional
file 3: PK/PD target attainment, Table S2). For doses of
1000 mg and 2000 mg, target attainment for the full MIC
range from 0.25 mg/L to 8 mg/L is summarised in Add-
itional file 3: PK/PD target attainment.
Impact of renal function on meropenem exposure and
target attainment
In addition to the large inter- and intra-patient variabil-
ity in meropenem exposure (i.e., C4h values [see Fig. 3a,
y-axis] and C8h values [see Fig. 3b, y-axis]), large variabil-
ity was also observed for RF, with representatives in all
RF classes from severe RI to augmented RF (see Fig. 3,
x-axes). In addition to the 41 non-CRRT patients, 7
CRRT patients were investigated. Whereas RF was stable
(i.e., constant RF class) within the monitored study
period for half of the patients (n = 24), RF of the other
half changed between two (npatients = 21) or even three
(npatients = 3) classes of RF. Already at the patient level, a
strong dependency between median individual CLCRCG
and C4h (see Fig. 3a1) and C8h (see Fig. 3b1) of the pa-
tients was found, interestingly also for the CRRT pa-
tients (see Fig. 3a2, b2). Also of note, in patients
undergoing ECMO, meropenem concentrations were
comparable with non-ECMO patients regarding their
median individual CLCRCG. Moreover, within most of
the individuals with changing RF, the same tendency of
higher meropenem exposure for decreased RF was ob-
served; for example, patient 34 had worsening of RF and
at the same time increasing meropenem exposure across
the 4 study days (see grey tick mark label in Fig. 3a1, b1).
At the sample level (i.e., when relating all single CLCRCG
values as a continuous variable to meropenem exposure
[C8h]), a distinct relation was found, which was described
by the hyperbolic function C8h ¼ 40363⋅ 1ðCLCRCGÞ2:27 (see
Fig. 3c; without C8h values of patient 36). Four C8h values
of one patient (patient 36) were excluded from the regres-
sion because they were considerably larger than those of
the remaining patients with similar RF; when including the
four values of this patient, the predicted C8h values in the
investigated CLCRCG range changed only negligibly for all
metrics (quantified CLCRCG-meropenem exposure rela-
tionship, 95% CI, 95% prediction interval) (see Additional
file 2: Regression model for risk calculation, Figure S2).
In non-CRRT patients, stratification of target attain-
ment by the RF classes identified augmented RF to mild
RI (CLCRCG > 130–60 ml/minute) as a risk factor for
Fig. 2 Meropenem serum concentrations vs. time after last dose
(n = 48 patients). Dark blue/red circles represent concentrations of
patients treated with 1000 mg/2000 mg meropenem. Light blue/
orange circles represent measured meropenem serum concentration
values at the end of the actual dosing interval among patients treated
with 1000 mg/2000 mg meropenem
Table 2 Inter- and intra-individual variability of meropenem concentrations at specific time points
Abbreviations: Cmin Measured meropenem serum concentration at end of actual dosing interval, CX Meropenem serum concentration at specific time point X of
concentration-time profile
Ehmann et al. Critical Care  (2017) 21:263 Page 7 of 14
non-attainment of both targets (target attainment 0–
46.2% for 100%T>MIC, 0–59.7% for 50%T>4×MIC) (see
Table 3) for infections with pathogens of MIC 2 mg/L.
Given an MIC of 8 mg/L, meropenem treatment re-
sulted in reliable target attainment only in the presence
of severe RI (CLCRCG 15–29 ml/minute); thus, already
moderate RI (CLCRCG 30–59 ml/minute) was identified
as a risk factor for target non-attainment (target attain-
ment for moderate RI 51.4% for 100%T>MIC, 12.5% for
50%T>4×MIC).
Risk assessment tool
The developed risk assessment tool, the MeroRisk Cal-
culator (beta version), is provided as Additional file 4
and is compatible with Windows operating systems and
Excel version 2010 and onwards. When opening the
tool, the user might be asked to enable macros, enable
content and add to trusted documents. The MeroRisk
Calculator is an easy-to-use, three-step Excel spread-
sheet (graphical user interface) which can be used to as-
sess the risk of target non-attainment of the PK/PD
index 100%T>MIC for non-CRRT patients (Fig. 4a). In
step 1, the user provides either the CLCRCG of a patient
or its determinants (sex, age, total body weight, serum
creatinine concentration), which will then be used to
calculate CLCRCG. In step 2, the user provides the MIC
value of a determined or suspected infecting pathogen,
which is used as the target meropenem concentration.
In cases in which the MIC value is not available, no MIC
value needs to be provided (for handling of blank MIC
entry, see next step). In step 3, the MeroRisk Calculator
computes the probability (“risk”) of target non-
attainment for the given CLCRCG and MIC value; if the
MIC entry was left blank, the user then has the option
to select a EUCAST MIC breakpoint for relevant bacteria
[36]. The calculated risk (rounded to integer) of target non-
attainment is displayed with the following three-colour cod-
ing system: green (≤10%), orange (>10% to < 50%) and red
(≥50%). In addition, the tool provides a graphical illustra-
tion of the quantified CLCRCG-C8h relationship including
the 95% prediction interval and predicts, on the basis of
provided/calculated CLCRCG, the most likely concentration
Table 3 Pharmacokinetic/pharmacodynamic target attainment for all patients not receiving continuous renal replacement therapy
and stratified by renal function
Abbreviations: CLCRCG Creatinine clearance estimated according to Cockcroft and Gault equation [34], CRRT Continuous renal replacement therapy, CX Concentration at
specific time point X of concentration-time profile, I/R Intermediate/resistant, PK/PD Pharmacokinetic/pharmacodynamic, RF Renal function, RI Renal impairment,
S/I Susceptible/intermediate
1Patients were assigned to a renal function class on the basis of their median individual CLCRCG at the time of C4h or C8h determination
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to which meropenem concentrations after multiple dosing
will decline before the next dosing (C8h) (see Fig. 4b; for fur-
ther details, see Additional file 2: Regression model for risk
calculation, section 2).
Discussion
We found a strong relationship between RF and merope-
nem exposure and consequently PK/PD target attain-
ment, and we developed a graphical user tool to predict
Fig. 3 Relationship between meropenem serum concentration and creatinine clearance. Meropenem serum concentrations 4 h (C4h) (a1, a2) and
8 h (C8h) (b1, b2, c) after start of infusion in non-CRRT (a1, b1, c) and CRRT (a2, b2) patients vs. median individual CLCRCG (patient level; a, b) or
vs. all single CLCRCG (sample level; c) of the patients. Tick mark of x-axis (a, b) represents median individual CLCRCG at time of determined C4h or
C8h value. Bold tick mark labels (a, b) represent ECMO patients. Grey tick mark labels (a1, b1) represent patient example mentioned in “Impact of
renal function on meropenem exposure and target attainment” section of main text. Coloured symbols (a-c) represent renal function class of a
patient at time of determined C4h or C8h value. Shaped symbols (a, b) represent study day on which C4h or C8h value was determined. Dashed
vertical lines/horizontal arrows (a-c) represent separation of renal function classes. Dashed horizontal lines (a-c) represent EUCAST MIC breakpoints
for Enterobacteriaceae, Pseudomonas spp. or Acinetobacter spp. (S/I 2 mg/L, I/R 8 mg/L [36]). Data points labelled with 36 (c) represent four C8h
values of patient 36. Black curve (c) represents quantified hyperbolic relationship between CLCRCG and C8h values, excluding data of patient 36.
Abbreviations: CLCRCG Creatinine clearance estimated according to Cockcroft and Gault [34]; CRRT Continuous renal replacement therapy; C4h
Meropenem serum concentration at 4 h after infusion start; C8h Meropenem serum concentration at 8 h after infusion start; ECMO Extracorporeal
membrane oxygenation; EUCAST European Committee on Antimicrobial Susceptibility Testing; ID Patient identifier; I/R Intermediate/resistant; MIC
Minimum inhibitory concentration; S/I Susceptible/intermediate
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the risk of target non-attainment under meropenem
standard dosing based on an ICU patient’s RF.
This work was focused on the analysis of the standard
dosing regimen for meropenem (1000 mg administered
as 30-minute infusions every 8 h) as the approved
and still most frequently used dosing regimen in ICUs
[12, 45]. To best represent the variety of different
ICU patients, the analysis was based on extensively
sampled data of a prospective observational study in-
cluding a large number of patients with highly hetero-
geneous patient-specific factors from different ICUs,
though at one single study centre.
Fig. 4 Graphical user interface of the MeroRisk Calculator. a Display when opening the tool (i.e., without any entries). b Display after risk calculation for
a specific patient: female, aged 60 years, body weight 65 kg, serum creatinine 0.6 mg/dl, infected with pathogen of MIC 2 mg/L. Abbreviations: CLCRCG
Creatinine clearance estimated according to Cockcroft and Gault equation [34], CRRT Continuous renal replacement therapy, C8h Meropenem serum
concentration 8 h after infusion start, MIC Minimum inhibitory concentration
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We showed large inter-individual variability in merope-
nem exposure, which was in accordance with previous
studies [22, 23]. The larger variability in concentrations of
the late phase compared with the earlier phase of the
concentration-time profile (variability: Cmin, C8h > C4h)
suggested that PK variability was due to variability in drug
elimination processes rather than in drug distribution.
This finding is supported by population PK analyses that
identified larger inter-individual variability on the PK par-
ameter clearance than on volume of distribution [24, 28].
The relatively long observation period of 4 days and the
large number of samples collected per patient in our study
additionally enabled the quantification of intra-individual
variability in meropenem exposure. Its large value led to
the hypothesis that meropenem exposure is influenced by
certain time-varying patient-specific factors such as con-
firmed in the present work by longitudinally measured
CLCRCG.
Our PK/PD analysis demonstrated that meropenem
standard dosing did not achieve the desired meropenem
PK/PD targets 100%T>MIC and 50%T>4×MIC in a consid-
erable fraction of patients. For pathogens of MIC 2 mg/
L, which represents the upper limit of the susceptible
range for many important bacteria [36], meropenem ex-
posure was inadequate in every second dosing interval
monitored. In line with our work, Carlier et al. found
similar results for the target 100%T>MIC given the same
MIC value (target attainment 55%) [25]. For infections
with less susceptible bacteria of MIC 8 mg/L (I/R break-
point [36]), which have been shown to commonly occur
in ICUs [8, 9], target non-attainment was high, with four
of five dosing intervals resulting in sub-therapeutic
concentrations (target 100%T>MIC). The target attain-
ment analysis with the two targets 100%T>MIC and
50%T>4×MIC revealed similar results. Of note, current
knowledge on PK/PD targets for meropenem in hetero-
geneous ICU populations is limited, and a PK/PD tar-
get for this special patient population has not been
derived yet. In relation to other PK/PD targets de-
rived for meropenem in diverse clinical studies (e.g.,
19.2%T>MIC and 47.9%T>MIC [21], 54%T>MIC [19] and 76-
100%T>MIC [20]), the two PK/PD targets selected for our
analysis were at the upper end (i.e., stricter). The selection
of the higher targets seemed reasonable, given (1) limited
knowledge on an adequate PK/PD target for heteroge-
neous ICU populations and (2) the high severity of illness
(median APACHE IIfirst study day 27) and the high propor-
tion of patients with transplants (~58%) in the evaluated
population. Indeed, these targets have been reported to
be commonly used in clinical practice for ICU patients
[40]. However, owing to the limited knowledge of PK/
PD targets in ICU patients, there is a crucial need to
explore which PK/PD target is best related to clinical
outcome in critically ill patients in a prospective clinical
trial. Further analyses should also be aimed at inves-
tigating differences in PK/PD targets between, for
example, different patient sub-groups (e.g., with vs.
without transplants), different states of severity of
illness or different types of infecting bacteria (gram-
positive vs. gram-negative) in a sufficiently large num-
ber of patients.
In line with other studies, we identified RF determined
by CLCRCG to influence meropenem exposure [26, 27,
29–31]. On the basis of the large number of longitudin-
ally measured meropenem serum concentrations and
CLCRCG values covering the full spectrum of RF classes,
we were able to quantify a hyperbolic relationship be-
tween CLCRCG and meropenem exposure. The present
study also included special patient groups such as CRRT
and ECMO patients. For CRRT patients, authors of
other publications identified measured CLCR deter-
mined via 24-h urine collection [28] or residual diuresis
[46] as influencing factors on meropenem exposure,
both requiring time-consuming urine collection. Al-
though our analysis included a rather small number of
CRRT patients, it revealed CLCRCG as a potential de-
terminant of meropenem exposure which can be
assessed more easily and quickly in clinical practice
than RF markers determined via 24-h urine collection.
This finding requires further investigation with a
larger number of patients under a well-designed
protocol. For the six ECMO patients, the relationship
between CLCRCG and meropenem concentrations did
not seem different from that of the remaining pa-
tients, suggesting that ECMO therapy did not have a
strong impact on meropenem serum exposure. This is
in line with findings reported by Donadello et al.
showing no significant difference between the PK
parameters of ECMO and control non-ECMO ICU
patients [47].
The impact of RF on the target attainment was overall
in accordance with the results of a recent publication by
Isla et al. [33], in which the probability of attaining the
target 100%T>MIC was analysed for three specific
CLCRCG values: Target attainment was 51% for CLCRCG
35 ml/minute (vs. 51% in our study for CLCRCG range
30–59 ml/minute), 3% for CLCRCG 71 ml/minute (vs.
4.6%, 60–89 ml/minute) and 0% for CLCRCG 100 ml/
minute (vs. 3.5%, 90–129 ml/minute) for an MIC 8 mg/
L. Because the present study included patients covering
the full spectrum of RF classes, additional investigation
of target attainment in extreme RF classes (severe RI,
augmented RF) was possible. For infections with bac-
teria of MIC 2 mg/L, augmented RF to mild RI was
identified as a risk factor of target non-attainment;
given bacteria of MIC 8 mg/L, moderate RI was an add-
itional risk factor. These findings imply the need for
dosing intensification in patients identified to be at risk
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of target non-attainment, such as by increasing the dose
or prolonged up to continuous infusion, which is currently
under clinical investigation; whereas some previous stu-
dies have associated continuous infusion with improved
clinical cure rates [48, 49], others have not shown a diffe-
rence in clinical outcome when comparing continuous
with intermittent dosing [50]. In this PK/PD analysis, the
only patient group that reliably reached the PK/PD targets
was the subgroup with severe RI. Notably, these patients
also received 1000 mg meropenem every 8 h as 30-minute
infusions and thus received higher doses than re-
commended in the summary of product characteristics
(half of indicated dose every 12 h for patients with
CLCRCG 10–25 ml/minute [12]).
To enable the practical application of the quantified
relationship between RF and meropenem exposure and
consequently target attainment, we developed a risk as-
sessment tool in a commonly available and known soft-
ware (see Additional file 4: MeroRisk Calculator, beta
version). This easy-to-use Excel tool allows assessment
of the risk of target non-attainment for non-CRRT pa-
tients displaying RF within a broad range (25–255 ml/
minute) and receiving standard dosing of meropenem
(1000 mg every 8 h as 30-minute infusions). We imple-
mented the risk of target non-attainment of meropenem
depending on creatinine clearance according to the
Cockcroft and Gault equation (CLCRCG [34]) and not
depending on creatinine clearance determined by 24-h
urine collection (CLCRUC [51]), because CLCRCG can be
assessed more easily in clinical practice, and the rela-
tionship between CLCRUC and meropenem exposure
was not better than between CLCRCG and meropenem
exposure (see Additional file 2: Figure S3). To apply the
tool, the user needs to provide only the CLCRCG or its
determinants (i.e., sex, age, total body weight and the
routinely determined laboratory value serum creatinine).
In addition, the MIC value of a bacterium determined or
suspected in the investigated patient needs to be pro-
vided. Should MIC values not be available, the user has
the option to select an MIC breakpoint for important
pathogens from the EUCAST database. Because only a
limited number of patients with augmented RF or severe
RI were included in this analysis, the uncertainty of the
CLCRCG-meropenem exposure relationship implemented
in the MeroRisk Calculator is higher for the extremes of
the RF spectrum. Furthermore, the user of the tool needs
to keep in mind that in addition to CLCRCG, other factors
might influence meropenem exposure. To visualise the
prediction uncertainty (i.e., uncertainty in the CLCRCG-
meropenem exposure relationship combined with the
variability in C8h values) of the calculated meropenem C8h
value for a patients CLCRCG, the prediction interval
around the CLCRCG-meropenem exposure relationship is
additionally provided in the risk assessment tool. Of
particular note, using the MeroRisk calculator does
not require the measurement of a meropenem con-
centration of a patient. In case of available merope-
nem concentrations in a patient, use of therapeutic
drug monitoring is encouraged to aid therapeutic de-
cision making [52]. The current beta version of the
MeroRisk Calculator is intended to be used in the
setting of clinical research and training. As a next
step, comprehensive prospective validation of the risk
calculator in clinical research setting is warranted.
Conclusions
Our PK/PD analysis demonstrated large inter- as well as
intra-patient variability in meropenem serum exposure
after standard dosing in critically ill patients. Standard
dosing was likely to result in sub-therapeutic meropenem
exposure in a considerable fraction of critically ill patients,
especially when assuming infections caused by less sus-
ceptible bacteria commonly encountered in these patients.
CLCRCG was identified as a vital clinical determinant of
meropenem exposure and consequently target attainment.
In the future, the newly developed risk assessment tool as
a graphical user interface (see Additional file 4: MeroRisk
Calculator) might, if all requirements are met, be benefi-
cial in clinical practice for therapeutic decision making.
An ICU patient’s risk of target non-attainment, given his/
her RF and the MIC value of the infecting pathogen,
would already be accessible when no meropenem concen-
tration measurement is available, such as prior to the start
of antibiotic therapy. Our findings indicate that dosing in-
tensification might be needed, depending on a patient’s RF
and the susceptibility of the infecting pathogen, and that
optimised dosing regimens should be further investigated
with respect to increased clinical benefit and reduced
development of resistance.
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